HomeActive Pharmaceutical Ingredients

Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A2663 Anti-IDO2 Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD.
A2665 Anrukinzumab (Anti-IL-13) Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD.
A2666 Anti-IL-13Ra2 / CD213a2 Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD.
A2923 Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
A2668 Etokimab (Anti-IL-33) Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD.
A2925 Anti-GPR64 / ADGRG2 Anti-GPR64 / ADGRG2 is a monoclonal antibody (mAb) against G protein-coupled receptor 64 isoform 4 (anti-GPR64) with potential anti-tumour activity. MW: 146.1.
A2672 Anti-MAGEA3 Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW :145.56 KD.
A2929 Anti-KID3 Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD.
A2681 Brontictuzumab (Anti-NOTCH1) Brontictuzumab (Anti-NOTCH1) is a monoclonal antibody that targets Notch1 signal. It inhibits tumor cell proliferation and can be used in the research of leukemia and lymphoma. MW :150 KD.
A2684 Anti-PDGFC / VEGFE Anti-PDGFC / VEGFE is a monoclonal antibody targeting PDGF-CC. It can be used in the research of cancer, fibrosis and neuropathologies. MW :145.9 KD.
A2689 Anti-RSPO1 Anti-RSPO1 is a monoclonal antibodies against R-spondin1 gene (RSPO1) with potential anti-tumor activity . MW: 150 KD.
A2691 Anti-SIRPa / CD172a Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD.
A2948 Nipocalimab (Anti-FcRn) (FCGRT & B2M) Nipocalimab (anti-FcRn) (FCGRT & B2M) is a fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. MW: 142.12 KD.
A2695 Anti-TGFb1 (M7824) Anti-TGFb1 (M7824) is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor beta 1 (TGFb1). It exhibits anti-tumor efficacy against breast and colon carcinomas.
A2700 Anti-CD48 Anti-CD48 is a monoclonal anti-CD48 antibody with the potential to treat treatment of allergic conditions and inflammatory conditions. MW: 144.22 KD.
A2705 Anti-vWF Anti-vWF is a monoclonal anti-VWF antibody with the potential to treat thrombotic thrombocytopenic purpura. MW: 145.62 KD.
A2961 Anti-F8 / Factor VIII Anti-F8 / Factor VIII is a monoclonal IgG anti-factor VIII antibody that hydrolyzes FVIII in acquired hemophilia. MW: 145.14 KD.
A2706 Anti-CXCR3 / GPR9 / CD183 Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.
A2708 Anti-TPSAB1 Anti-TPSAB1 is a humanized monoclonal antibody against human β-tryptase with the potential to treat mast cell-mediated severe asthma. MW: 150 KD.
A2709 Anti-GPR44 / PTGDR2 / CD294 Anti-GPR44 / PTGDR2 / CD294 is a monoclonal antibody against a transmembrane G-protein-coupled receptor (GPR44, also known as CRTH2, PTGDR2,or CD294) with the potential to treat asthma. MW: 147.66 KD.